Abstract
The classification of adeno-pituitary tumor was deeply revised over the last 20 years, in order to better describe the variable and complex biological and clinical behavior of these neoplasia and to identify prognostic markers of aggressiveness and poor prognosis. Recently, the International Pituitary Pathology Club proposed to replace the term “pituitary adenoma” with “pituitary neuroendocrine tumour” (PitNET), to reflect similarities of adeno-pituitary tumours with neuroendocrine neoplasia of other organs, underling better the variable behaviour of adeno-pituitary neoplasia. A definitive consensus was not reached on this issue. In this review, we will describe how molecular and biological marker can predict aggressiveness of PitNETs and impact on therapeutic management of PitNETs.
Keywords: Hyperprolactinemia, prolactinoma, acromegaly, cushing, hypercortisolism, gonadotropinoma, somatostatin receptor, somatostatin analogues.
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title:From Pituitary Adenoma to Pituitary Neuroendocrine Tumors: How Molecular Pathways may Impact the Therapeutic Management?
Volume: 21 Issue: 10
Author(s): Sabrina Chiloiro and Laura De Marinis*
Affiliation:
- UOS di Patologia Ipotalamo-Ipofisaria, Dipartimento di Medicina e Chirurgia traslazionale, Università Cattolica del Sacro Cuore, Rome,Italy
Keywords: Hyperprolactinemia, prolactinoma, acromegaly, cushing, hypercortisolism, gonadotropinoma, somatostatin receptor, somatostatin analogues.
Abstract: The classification of adeno-pituitary tumor was deeply revised over the last 20 years, in order to better describe the variable and complex biological and clinical behavior of these neoplasia and to identify prognostic markers of aggressiveness and poor prognosis. Recently, the International Pituitary Pathology Club proposed to replace the term “pituitary adenoma” with “pituitary neuroendocrine tumour” (PitNET), to reflect similarities of adeno-pituitary tumours with neuroendocrine neoplasia of other organs, underling better the variable behaviour of adeno-pituitary neoplasia. A definitive consensus was not reached on this issue. In this review, we will describe how molecular and biological marker can predict aggressiveness of PitNETs and impact on therapeutic management of PitNETs.
Export Options
About this article
Cite this article as:
Chiloiro Sabrina and De Marinis Laura *, From Pituitary Adenoma to Pituitary Neuroendocrine Tumors: How Molecular Pathways may Impact the Therapeutic Management?, Endocrine, Metabolic & Immune Disorders - Drug Targets 2021; 21 (10) . https://dx.doi.org/10.2174/1871530321666210226152901
DOI https://dx.doi.org/10.2174/1871530321666210226152901 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial (Thematic Issue: Myokines and Exercise Training: More Shadows than Lights)
Current Pharmaceutical Design ImmunoPET in Neoplasms of Gastrointestinal Tract, Liver and Pancreas in the XXIst Century: Bridging the Gap Between Diagnosis and Therapy
Reviews on Recent Clinical Trials A Review on Hematopoietic Stem Cell Treatment for Epilepsy
CNS & Neurological Disorders - Drug Targets Recent Advances in Drug Design of Epidermal Growth Factor Receptor Inhibitors
Current Medicinal Chemistry Polymer Particulates in Drug Delivery
Current Pharmaceutical Design Drug Resistance: Challenges to Effective Therapy
Current Cancer Drug Targets The Adjunctive Value of Diffusion Weighted Imaging in Diagnosis and Follow Up of Uterovaginal Diffuse B-cell Lymphoma: A Case Report and Literature Review
Current Medical Imaging Signalling Pathways Activated by Ultraviolet Radiation: Role in Ocular and Cutaneous Health
Current Pharmaceutical Design Integrins: A Method of Early Intervention in the Treatment of Colorectal Liver Metastases
Current Pharmaceutical Design Cancer Stem Cells in Solid and Liquid Tissues of Breast Cancer Patients: Characterization and Therapeutic Perspectives
Current Cancer Drug Targets Graphene Oxide: A Carrier for Pharmaceuticals and a Scaffold for Cell Interactions
Current Topics in Medicinal Chemistry Anatomical, Biochemical and Physiological Considerations of the Colon in Design and Development of Novel Drug Delivery Systems
Current Drug Delivery Tyrosine Kinase Inhibitors
Current Cancer Drug Targets Monoclonal Antibodies as Cancer Therapeutics
Recent Patents on Biotechnology Dietary Habits of Mongolian People, and Their Influence on Lifestyle-Related Diseases and Early Aging
Current Aging Science Pin1: A New Genetic Link between Alzheimer’s Disease, Cancer and Aging
Current Aging Science Radiosensitizing Potential of Epigenetic Anticancer Drugs
Anti-Cancer Agents in Medicinal Chemistry Genetics and Epigenetics of Lung Cancer: Mechanisms and Future Perspectives
Current Cancer Therapy Reviews An Overview of Emerging Immunotargets of Genitourinary Tumors
Current Drug Targets Pharmacogenetics and Inflammatory Bowel Disease
Current Pharmacogenomics and Personalized Medicine